Research & Development

CEPI to provide up to $328m for development of Clover’s Covid-19 vaccine candidate

The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to provide up to $328m to Clover Biopharmaceuticals for the development of Covid-19 vaccine candidate.

Sanofi offers to acquire clinical-stage company Kiadis

Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell based medicines for the treatment of life-threatening diseases, entered into a definitive agreement under which Sanofi will make a public offer (subject to satisfaction of certain customary conditions) to acquire the entire share capital of Kiadis for EUR 5.45 per share, representing an aggregate adjusted equity value of €308m.

PerkinElmer to buy cell engineering firm Horizon Discovery for $383m

US-based PerkinElmer has agreed to acquire UK-based cell engineering company Horizon Discovery Group in a deal valued at around $383m.

Novartis buys gene therapy company Vedere Bio for up to $280m

Swiss pharmaceutical company Novartis has acquired gene therapy company Vedere Bio in a deal valued at around $280m.

Bristol Myers Squibb, insitro partner to develop treatments for neurodegenerative disorders

Machine-learning driven drug discovery and development company insitro has entered into a five-year collaboration with Bristol Myers Squibb to develop treatments for neurodegenerative disorders.

Novartis collaborates with Molecular Partners to develop two DARPin therapies designed for Covid-19

Novartis and Molecular Partners announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423.

Bayer to acquire Asklepios BioPharmaceutical for up to $4bn

German pharmaceutical and life sciences company Bayer has agreed to acquire US-based clinical-stage gene therapy company Asklepios BioPharmaceutical (AskBio) for up to $4bn.

Sirnaomics seals $105m Series D financing for RNAi therapeutics

Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed its USD$105 million Series D financing.

EffRx Pharmaceuticals signs exclusive license agreement with Diurnal for registration and commercialisation of Alkindi

EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, for the registration and commercialization of Alkindi for pediatric adrenocortical insufficiency (AI) in Switzerland.